Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

0.3763
-0.3037-44.66%
Post-market: 0.3645-0.0118-3.14%19:57 EST
Volume:3.93M
Turnover:1.41M
Market Cap:2.95M
PE:-0.10
High:0.4183
Open:0.4000
Low:0.3105
Close:0.6800
52wk High:5.55
52wk Low:0.3105
Shares:7.85M
Float Shares:3.16M
Volume Ratio:32.58
T/O Rate:124.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7603
EPS(LYR):-48.9723
ROE:-2264.31%
ROA:-89.29%
PB:0.83
PE(LYR):-0.01

Loading ...

Ernexa Therapeutics prices 21M shares at 50c in public offering

TIPRANKS
·
Yesterday

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

GlobeNewswire
·
Yesterday

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

GlobeNewswire
·
Feb 03

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

GlobeNewswire
·
Jan 27

BRIEF-Ernexa Therapeutics Announces Successful Pre-Ind FDA Meeting

Reuters
·
Jan 06

Eterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2

MT Newswires Live
·
Jan 06

Ernexa Therapeutics Receives FDA Alignment to Advance Ovarian Cancer Cell Therapy Trial

Reuters
·
Jan 06

Ernexa Therapeutics Announces Successful Pre-Ind FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

THOMSON REUTERS
·
Jan 06

Ernexa Therapeutics Inc - on Track to Initiate Fih Trial for Ovarian Cancer in 2026

THOMSON REUTERS
·
Jan 06

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

GlobeNewswire
·
Dec 08, 2025

BRIEF-Ernexa Therapeutics Announces Oral Presentation At The 67Th American Society Of Hematology

Reuters
·
Dec 03, 2025

Ernexa Therapeutics Announces Oral Presentation at the 67TH American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
Dec 03, 2025

Press Release: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

Dow Jones
·
Dec 02, 2025

Ernexa Therapeutics to Present at Oxford Global’s Cell 2025

GlobeNewswire
·
Nov 11, 2025

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

GlobeNewswire
·
Nov 10, 2025

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

GlobeNewswire
·
Nov 06, 2025

BRIEF-Cellipont Bioservices And Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership To Advance Erna-101 Toward Clinical Trials In Ovarian Cancer

Reuters
·
Oct 29, 2025

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance Erna-101 Toward Clinical Trials in Ovarian Cancer

THOMSON REUTERS
·
Oct 29, 2025

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

GlobeNewswire
·
Oct 01, 2025

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

GlobeNewswire
·
Sep 29, 2025